Preclinical analysis of burnzymes, enzymes for the treatment of infections in burn wounds
As stated by several independent studies, an increasing number of species and strains of bacteria are acquiring resistance towards one or multiple antibacterial agents. As a result, it is expected that when no action is taken, in 2050, more people will die from previous curable diseases than that people will die from cancer nowadays. This is the reason why in this PhD, a new antibacterial strategy will be explored. More specifically, the aim is to develop an antibacterial agent active against three pathogens (Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus) frequently found in burn wound infections. This will be done by combining several (bacteriophage-derived) proteins. These pathogens form also a direct threat to human health as stated by the WHO labeling them as pathogens with high to critical priority regarding the discovery and development of new drugs. Additionally, these antibacterial agents will be engineered in order to posess anti-inflammatory and antibiofilm properties. After obtaining promising combinations, these combinations will be used in preclinical trials in order to end up with a new generation of antibacterials spanning the gap between Gram-positive and Gram-negative pathogens.